Home  About us  Contact
 

Q Fever (q + fever)

Distribution by Scientific Domains
Medical Sciences100%

Kinds of Q Fever

  • acute q fever
    		•

    Selected Abstracts

    Acute Q fever in pregnancy: report and literature review

    INTERNAL MEDICINE JOURNAL, Issue 7 2009
    J. Denman
    Abstract Acute Q fever in pregnancy is uncommon, but is probably underrecognized. It results in a significant risk of adverse pregnancy outcome and also predisposes to the development of chronic Q fever in the mother. Here, we review the clinical features, epidemiology, treatment and follow-up of acute Q fever in pregnancy. The potential for transmission of Coxiella to the neonate and birthing suite staff will also be highlighted. [source]

    Histopathology of a granulomatous lobular panniculitis in acute Q fever: a case report

    JOURNAL OF CUTANEOUS PATHOLOGY, Issue 8 2010
    R Soulard
    Q fever is a zoonotic infection caused by Coxiella burnetii. Two forms of the disease have been described: an acute form with pneumonia, hepatitis or a flu-like syndrome; and a chronic form in which endocarditis is the most frequent clinical expression. We report a 77 year old male with fever and an erythematous nodule on the right leg. Biopsy revealed a granulomatous lobular panniculitis with some granulomas rimmed by an eosinophilic material, giving a "doughnut" or "fibrin-ring" appearance. Q fever serological studies were positive. Cutaneous signs, among them panniculitis, are probably underestimated during the acute phase of the disease, and recognizing different granulomatous patterns may contribute to the diagnosis. Soulard R. Histopathology of a granulomatous lobular panniculitis in acute Q fever: a case report. [source]

    Coxiella burnetii lymphadenitis: A possible fever focus in acute Q fever

    PEDIATRICS INTERNATIONAL, Issue 6 2000
    Tadashi Ariga
    First page of article [source]

    A serosurvey of Coxiella burnetii infection in children and young adults in South West Queensland

    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, Issue 1 2010
    Neil Parker
    Abstract Objective: To describe the seroepidemiology of Coxiella burnetii, the causative agent of Q fever, in those under 25 years of age in South West Queensland. Methods: A convenience sample of residual sera from a diagnostic laboratory was tested for C. burnetii antibodies by immunofluorescence at 1:10 dilution. Prevalence and annual incidence were calculated from the results. Results: Twenty-nine of 447 (6.5%, 95% CI 4.5%-9.2%) samples were positive. Seropositivity increased from 2.5% in those <15 (95% CI 1.0%-5.5%) to 11.0% in those 15-24 years old (95% CI 7.4%-16.0%). The estimated annual incidence for the latter age group was 7.7 per 1,000. Conclusions: Q fever is a relatively common infection in South West Queensland, even in those aged <15 years for whom the vaccine is not recommended. Implications: Vaccination programs, such as the federally funded National Q fever Management Program, are needed in this and similar high risk rural areas. [source]

    Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents

    BRITISH JOURNAL OF PHARMACOLOGY, Issue 4 2010
    S Ramasamy
    The use of biological agents has generally been confined to military-led conflicts. However, there has been an increase in non-state-based terrorism, including the use of asymmetric warfare, such as biological agents in the past few decades. Thus, it is becoming increasingly important to consider strategies for preventing and preparing for attacks by insurgents, such as the development of pre- and post-exposure medical countermeasures. There are a wide range of prophylactics and treatments being investigated to combat the effects of biological agents. These include antibiotics (for both conventional and unconventional use), antibodies, anti-virals, immunomodulators, nucleic acids (analogues, antisense, ribozymes and DNAzymes), bacteriophage therapy and micro-encapsulation. While vaccines are commercially available for the prevention of anthrax, cholera, plague, Q fever and smallpox, there are no licensed vaccines available for use in the case of botulinum toxins, viral encephalitis, melioidosis or ricin. Antibiotics are still recommended as the mainstay treatment following exposure to anthrax, plague, Q fever and melioidosis. Anti-toxin therapy and anti-virals may be used in the case of botulinum toxins or smallpox respectively. However, supportive care is the only, or mainstay, post-exposure treatment for cholera, viral encephalitis and ricin , a recommendation that has not changed in decades. Indeed, with the difficulty that antibiotic resistance poses, the development and further evaluation of techniques and atypical pharmaceuticals are fundamental to the development of prophylaxis and post-exposure treatment options. The aim of this review is to present an update on prophylaxis and post-exposure treatment recommendations and research initiatives for biological agents in the open literature from 2007 to 2009. [source]

    Acute Q fever in hospitalised patients in Central Tunisia: report of 21 cases

    CLINICAL MICROBIOLOGY AND INFECTION, Issue 2009
    F. Bellazreg
    No abstract is available for this article. [source]